COVID-19 B.C. MEDICAL SUPPLIERS, LABORATORIES AND SERVICE PROVIDERS

June 29, 2020

June 29, 2020 – Vancouver, B.C. –  A huge thank you to BC’s life sciences community for the ongoing support in our collective efforts to conquer Covid-19 and restart economies.   On so many levels and within so many programs and initiatives…leadership, innovation, and commitment continue to inspire and impact.  As LSBC transitions to new activities, … Continue reading COVID-19 B.C. MEDICAL SUPPLIERS, LABORATORIES AND SERVICE PROVIDERS

adMare BioInnovations Strengthens Leadership Team

June 26, 2020
adMare BioInnovations

June 26, 2020 – adMare BioInnovations, Canada’s global life sciences venture, is pleased to announce the appointment to its leadership team of Dr. Laura McIntosh as Venture Partner, Montreal, and Linda Downs as Vice President, Human Resources. Laura McIntosh brings more than 15 years of executive-level R&D and product development experience to adMare. With a … Continue reading adMare BioInnovations Strengthens Leadership Team

InMed Introduces IntegraSynTM: An Integrated Cannabinoid Manufacturing System

June 24, 2020
InMed Pharmaceuticals Inc.

Vancouver, BC – June 24, 2020 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (“CBN”), today introduced details of IntegraSynTM, the Company’s new approach to producing pharmaceutical-grade cannabinoids. IntegraSynTM is … Continue reading InMed Introduces IntegraSynTM: An Integrated Cannabinoid Manufacturing System

DelMar Pharmaceuticals Receives $500,000 Loan from the National Brain Tumor Society and National Foundation for Cancer Research to Support VAL-083’s Participation in a Pivotal Study for Glioblastoma Sponsored by the Global Coalition for Adaptive Research

June 24, 2020
DelMar Pharmaceuticals Inc.

SAN DIEGO, June 24, 2020 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies announced today it has received a $500,000 loan from the National Brain Tumor Society (NBTS) and the National Foundation for Cancer Research (NFCR) to support VAL-083’s preparation for participation in … Continue reading DelMar Pharmaceuticals Receives $500,000 Loan from the National Brain Tumor Society and National Foundation for Cancer Research to Support VAL-083’s Participation in a Pivotal Study for Glioblastoma Sponsored by the Global Coalition for Adaptive Research

Building Canada’s Leadership Talent Amidst a COVID World

June 24, 2020
adMare BioInnovations

One week left to apply to adMare’s 2020-2021 Executive Institute June 23, 2020  – adMare BioInnovations, Canada’s global life sciences venture, is proud to continue to build on its highly-successful Executive Institute, a 10-month, highly-focused executive development program custom– designed to grow the management talent needed for Canadian life sciences to lead the world — … Continue reading Building Canada’s Leadership Talent Amidst a COVID World

Aurinia Completes Patient Enrollment Into the AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome

June 22, 2020
Aurinia Pharmaceuticals Inc.

Voclosporin ophthalmic solution (VOS) results anticipated in the fourth quarter of 2020 – VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications, today announced it has completed enrollment for the Phase 2/3 AUDREY™ clinical trial evaluating voclosporin … Continue reading Aurinia Completes Patient Enrollment Into the AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome

DelMar Pharmaceuticals Presents Positive Interim Data on VAL-083 Demonstrating Favorable Outcomes in Both Newly- Diagnosed and Recurrent GBM at the AACR Virtual Annual Meeting II

June 22, 2020
DelMar Pharmaceuticals Inc.

Findings Support Commencement of VAL-083’s Participation in Pivotal GCAR GBM AGILE Study SAN DIEGO, June 22, 2020 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced positive interim data from its two Phase 2 trials of VAL-083 for the treatment … Continue reading DelMar Pharmaceuticals Presents Positive Interim Data on VAL-083 Demonstrating Favorable Outcomes in Both Newly- Diagnosed and Recurrent GBM at the AACR Virtual Annual Meeting II

Neoleukin Therapeutics Presents Preclinical Data for NL-201 and De Novo Protein Design Technology at American Association for Cancer Research (AACR) Virtual Annual Meeting II

June 22, 2020
Neoleukin Therapeutics, Inc.

NL-201 demonstrates durable antitumor activity in animal tumor models – – NL-201 and targeted variants improve outcomes when combined with CAR-T cells in vivo – – Conditional activation of de novo proteins using split molecule technology may increase therapeutic index – – Company to host Investor R&D Showcase Tuesday, June 23 at 3:30 p.m. PT / 6:30 p.m. ET SEATTLE, June 22, … Continue reading Neoleukin Therapeutics Presents Preclinical Data for NL-201 and De Novo Protein Design Technology at American Association for Cancer Research (AACR) Virtual Annual Meeting II

InMed Announces Filing of Registration Statement in Connection with United States Offering, Application to Seek Nasdaq Listing and Planned Share Consolidation

June 22, 2020
InMed Pharmaceuticals Inc.

Vancouver, BC – June 19, 2020 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (“CBN”), today announced that it has filed a registration statement on Form S-1 with the United … Continue reading InMed Announces Filing of Registration Statement in Connection with United States Offering, Application to Seek Nasdaq Listing and Planned Share Consolidation

IMC responds to the release of revised PMPRB guidelines

June 19, 2020
Innovative Medicines Canada (IMC)

Ottawa, June 19, 2020 – Innovative Medicines Canada released the following statement today in response to the release of revised PMPRB pricing guidelines: “We have just received the revised Guidelines and we will be examining them closely, in consultation with our members, after which we will be in a position to comment in more detail. “We remain … Continue reading IMC responds to the release of revised PMPRB guidelines